Skip to main content
Fig. 6 | Human Genomics

Fig. 6

From: Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression

Fig. 6

Differential expression of immune checkpoints and response to ICIs and chemotherapy between two risk groups. A Box plot presenting the expression of 35 immune checkpoints in low- and high-risk groups. B–E Kaplan–Meier OS curves among four patient groups stratified by the 6 SE-lncRNAs risk signature and PD1 (B), CTLA4 (C), PD-L1 (D), and PD-L2 (E). F–I The relationship between IPS and the 6 SE-lncRNA signature of glioma patients. Distribution plot of IPS score (F), IPS-CTLA4 blocker score (G), IPS-PD1/PDL1/PDL2 blocker score (H), and IPS-CTLA4 and PD1/PDL1/PDL2 blocker score (I) were shown. (J) Submap analysis demonstrated that the high-risk group was more sensitive to anti-CTLA-4 therapy (P < 0.05). K–O The SE-lncRNA signature could serve as a potential indicator to evaluate the sensitivity to cisplatin (K), dasatinib (L), etoposide (M), paclitaxel (N), and doxorubicin (O). *p < 0.05, **p < 0.01, ***p < 0.001 and ns indicates no significance

Back to article page

Human Genomics

ISSN: 1479-7364